Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: A meta-analysis

Tsantes, Argirios Ε.; Nikolopoulos, Georgios K.; Bagos, Pantelis G.; Vaiopoulos, G; Travlou, Αnthi

doi:10.1016/j.ijcard.2006.06.047

Cited by 25 publications

(16 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The association of the T allele and TT genotype with acute coronary syndrome was also demonstrated in other case-control [77][78][79][80] and prospective studies [81], mainly concentrating on the white populations, with only one small study involving Chinese CAD patients [80]. Alongside with these studies, there are also reports with negative results [82], which may be due to the varying interactions of polymorphic genotypes with environmental factors. In fact, the thrombogenic effect of the T allele in positive studies was pronounced among relatively young subjects [76] and in the presence of risk factors such as smoking, hypertension or diabetes, and angiographically confirmed CAD [79].…”

Section: Gpia/iia Polymorphismmentioning

confidence: 73%

Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms

Shanker

Gasparyan²,

Kitas³

et al. 2011

CVP

View full text Add to dashboard Cite

Platelets play a crucial role in thrombosis, inflammation, immunity and atherogenesis. Antiplatelet agents are widely used in patients with acute coronary syndrome and other cardiovascular disorders. Aspirin and clopidogrel are the most commonly prescribed antiplatelet agents, with a relatively safe profile and efficiency in a variety of clinical conditions. Numerous prospective studies have revealed variability of antiplatelet efficacy. The so called "antiplatelet resistance" prompted a search for mechanisms implicated in poor responsiveness to aspirin and clopidogrel therapy. In this regard, genetic polymorphisms in the platelet receptor genes attracted considerable interest. Specific genetic variants in platelet receptors such as the P2Y12, glycoprotein (GP) IIb/IIIa, GPIa/IIa, GPIb/IX/V and the cytochrome P450 (CYP) family of genes are associated with variable response to antiplatelet therapy and cardiovascular events. Genetic polymorphisms and haplotypes that comprehensively capture the genetic information encoded within the platelet receptor genes can, to some extent, predict response to the antiplatelet drug better than any single genotype. Genotyping for multiple receptor variants in patients on antiplatelet therapy, complemented by standardized quantification of platelet function, can provide useful information for future drug design studies and possibly for personalized antiplatelet therapy and prevention of thrombotic events. Additional information is, however, needed to evaluate the cost-effectiveness of complex genetic and platelet function testing.

show abstract

Section: Gpia/iia Polymorphismmentioning

confidence: 73%

Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms

Shanker

Gasparyan²,

Kitas³

et al. 2011

CVP

View full text Add to dashboard Cite

show abstract

“…Okumus et al studied 77 patients who are suffering from VTE and 106 healthy controls for GPIa 807C/T polymorphism and reported that this polymorphism is not associated with DVT [17]. Several investigations failed to find a relationship between GPIa 807C/T polymorphism and VTE [18,19,30,31]. Therefore, it is conceivable that this polymorphism is not a risk factor for DVT.…”

Section: Discussionmentioning

confidence: 99%

Genetic susceptibility to deep venous thromboembolism

Bargahi

Ghorbian

Zonouzi

et al. 2016

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Recently much attention has been paid to the possibly considerable role of the thrombophilic gene polymorphisms in the pathogenesis of deep venous thromboembolism (DVT). However, the reported results are controversial. Hence, this study aimed to disclose the association between factor VII (FVII) 10976G/A, angiotensin-converting enzyme (ACE; intron 16 I/D), glycoprotein Ia (GPIa) 807C/T, tissue-type plasminogen activator (t-PA; intron 8 D/I) and tissue-factor pathway inhibitor 536C/T polymorphisms and DVT. We investigated these gene polymorphisms in 693 study participants including 193 patients who showed clinical symptoms of DVT and 500 healthy individuals without both personal and family histories of thromboembolic disorders. Genotyping was performed using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique. Comparison of genotypes distribution revealed that the FVII 10976G/A polymorphism was significantly related with DVT (P < 0.05), whereas there was no association between the ACE (intron 16 I/D), GPIa807C/T, t-PA (intron 8 D/I) and tissue-factor pathway inhibitor 536C/T gene polymorphisms and DVT (P > 0.05). In addition, the prevalence of homozygote genotype and mutant allele for FVII 10976G/A polymorphism was significantly higher in cases compared with controls (P < 0.05). Taken together, our data provide evidence to support the hypothesis that FVII 10976G/A polymorphism may be associated with a predisposition to DVT.

show abstract

“…Recently, a metaanalysis of 19 studies (total sample of 13 835 participants) demonstrated that the C807T polymorphism is not a significant risk factor for CAD: 807C allele vs. 807T allele, with an OR of 0.998 (95% CI 0.937-1.064) [22]. Another meta-analysis of 15 studies (total sample 14 146 participants) showed no effect of the C807T polymorphism on coronary disease [23]. Therefore, it is currently thought that this polymorphism is not associated with atherothrombosis in some populations.…”

Section: Discussionmentioning

confidence: 99%

Association of platelet collagen receptor polymorphisms with premature acute myocardial infarction

Kazemi

Fatemi²,

Givtaj³

et al. 2012

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

The impact of platelet collagen receptor polymorphisms in the pathogenesis of myocardial infarction at young age remains unknown. To determine whether either of the two platelet collagen receptor polymorphisms (GP VI T13254C and GP Ia C807T) was associated with premature acute myocardial infarction. One hundred patients with premature acute myocardial infarction and 100 age-matched controls with normal coronary angiograms were studied. Genotyping was done using PCR followed by restriction fragment length polymorphism (RFLP). GP Ia C807T polymorphism was more frequent in the patient group (65%) than in the control group (53%). However, there was no association between this polymorphism and premature acute myocardial infarction (P = 0.08). The prevalence of T13254C polymorphism did not differ between patients (38%) and controls (33%), and this polymorphism was not associated with premature acute myocardial infarction (P = 0.46). Logistic regression analysis also indicated no association between these polymorphisms and premature acute myocardial infarction (C807T with P = 0.51 and T13254C with P = 0.20). There is no association between GP VI T13254C or GP Ia C807T polymorphisms and premature acute myocardial infarction.

show abstract

Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: A meta-analysis

Cited by 25 publications

References 38 publications

Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms

Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms

Genetic susceptibility to deep venous thromboembolism

Association of platelet collagen receptor polymorphisms with premature acute myocardial infarction

Contact Info

Product

Resources

About